CRISPR Therapeutics AG, a biotechnology company, has entered into a significant investment agreement with certain institutional investors on February 13, 2024. The agreement involves the issuance of 3,916,082 common shares at a par value of CHF 0.03 per share, with the shares being offered at a price of $71.50 each. This offering is expected to generate gross proceeds of approximately $280 million before the deduction of estimated offering expenses. The transaction is supported by a shelf registration statement previously filed with the SEC on July 29, 2021. The investment agreement includes standard representations, warranties, closing conditions, termination clauses, and indemnification obligations. The details of the agreement are disclosed in the company's Form 8-K filing with the SEC, along with the legal opinion of Walder Wyss AG regarding the share issuance.

CRISPR Therapeutics AG, a biotechnology company, has entered into a significant investment agreement with certain institutional investors on February 13, 2024. The agreement involves the issuance of 3,916,082 common shares at a par value of CHF 0.03 per share, with the shares being offered at a price of $71.50 each. This offering is expected to generate gross proceeds of approximately $280 million before the deduction of estimated offering expenses. The transaction is supported by a shelf registration statement previously filed with the SEC on July 29, 2021. The investment agreement includes standard representations, warranties, closing conditions, termination clauses, and indemnification obligations. The details of the agreement are disclosed in the company's Form 8-K filing with the SEC, along with the legal opinion of Walder Wyss AG regarding the share issuance.